MIF and gastric cancer: These results indicate that ZFPM2-AS1 serves as an emerging oncogene in gastric cancer by protecting ZFPM2-AS1-induced MIF, providing a novel biomarker for diagnosis and a therapeutic target for gastric cancer 45.